Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylamine SCHEMBL8654778 | 0.86 | TLR8 (0.47) | METAP2ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL2096744 | 0.82 | METAP2 (0.33) | METAP2ALDH1A1HPGDGAAHSD17B10 | |
| SCHEMBL1502098 | 0.81 | ALOX5AP (0.40) | HSD17B10ALOX15CDK5CDK5R1CA1 | |
| Benzene SCHEMBL27958568 | 0.81 | GUSB (0.45) | ALDH1A1HPGDHSD17B10MAPTL3MBTL1 | |
| SCHEMBL6524744 | 0.80 | PDE5A (0.48) | ALDH1A1HPGDGAAHSD17B10ALOX15 | |
| SCHEMBL1948580 | 0.80 | IDO1 (0.42) | METAP2CYP19A1 | |
| SCHEMBL1948772 | 0.80 | HSP90AA1 (0.41) | ALDH1A1HPGDHSD17B10MAPTALOX15 | |
| SCHEMBL4786157 | 0.79 | KDM4E (0.33) | METAP2HPGDHTR3ACDK1CCNB1 | |
| SCHEMBL1949699 | 0.78 | GPR84 (0.47) | METAP2ALDH1A1MAPTL3MBTL1CNR2 | |
| SCHEMBL22434766 | 0.78 | ACHE (0.44) | ALDH1A1HPGDMAPTALOX12HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | THE INSTITUTE OF MOLECULAR MEDICINE (IN) | 2011-03-10 | — | — | US | disclosed |
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | THE INSTITUTE OF MOLECULAR MEDICINE (IN) | 2011-03-10 | — | — | US | disclosed |
| WO-2009091324-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATES AS ANTI-MYCOBACTERIAL AGENTS | CHATTOPADHYAYA JYOTI (SE) | 2009-07-23 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-6100404-A | Erythromycin compounds | HOECHST MARION ROUSSEL (FR) | 2000-08-08 | — | — | US | disclosed |
| EP-0680967-B1 | Erythromycin derivatives, their process of preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (FR) | 1998-10-14 | — | — | EP | disclosed |
| US-5635485-A | Erythromycin compounds | ROUSSEL UCLAF (FR) | 1997-06-03 | — | — | US | disclosed |
| WO-1995029929-A1 | NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS | ROUSSEL UCLAF (FR) | 1995-11-09 | — | — | WO | disclosed |
| EP-0680967-A1 | Erythromycin derivatives, their process of preparation and their use as medicaments | ROUSSEL-UCLAF (FR) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059948-A1 | QUINOLINE, NAPHTHALENE AND CONFORMATIONALLY CONSTRAINED QUINOLINE OR NAPHTHALENE DERIVATIVES AS ANTI-MYCOBACTERIAL AGENTS | NQO1, NQO2, NDUFV1 | METAP2 3817/4885ALDH1A1 1830/4885HPGD 98/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | METAP2 4360/4885ALDH1A1 412/4885HPGD 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.